These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 11429164)

  • 1. Recombinant, soluble LIGHT (HVEM ligand) induces increased IL-8 secretion and growth arrest in A375 melanoma cells.
    Hehlgans T; Männel DN
    J Interferon Cytokine Res; 2001 May; 21(5):333-8. PubMed ID: 11429164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphtoxin beta receptor-Ig ameliorates TNBS-induced colitis via blocking LIGHT/HVEM signaling.
    An MM; Fan KX; Zhang JD; Li HJ; Song SC; Liu BG; Gao PH; Zhou Q; Jiang YY
    Pharmacol Res; 2005 Sep; 52(3):234-44. PubMed ID: 15925518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proinflammatory effects of LIGHT through HVEM and LTbetaR interactions in cultured human umbilical vein endothelial cells.
    Chang YH; Hsieh SL; Chao Y; Chou YC; Lin WW
    J Biomed Sci; 2005; 12(2):363-75. PubMed ID: 15917993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the lymphotoxin beta receptor by cross-linking induces chemokine production and growth arrest in A375 melanoma cells.
    Degli-Esposti MA; Davis-Smith T; Din WS; Smolak PJ; Goodwin RG; Smith CA
    J Immunol; 1997 Feb; 158(4):1756-62. PubMed ID: 9029113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer.
    Zhai Y; Guo R; Hsu TL; Yu GL; Ni J; Kwon BS; Jiang GW; Lu J; Tan J; Ugustus M; Carter K; Rojas L; Zhu F; Lincoln C; Endress G; Xing L; Wang S; Oh KO; Gentz R; Ruben S; Lippman ME; Hsieh SL; Yang D
    J Clin Invest; 1998 Sep; 102(6):1142-51. PubMed ID: 9739048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reciprocal expression of the TNF family receptor herpes virus entry mediator and its ligand LIGHT on activated T cells: LIGHT down-regulates its own receptor.
    Morel Y; Schiano de Colella JM; Harrop J; Deen KC; Holmes SD; Wattam TA; Khandekar SS; Truneh A; Sweet RW; Gastaut JA; Olive D; Costello RT
    J Immunol; 2000 Oct; 165(8):4397-404. PubMed ID: 11035077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth.
    Harrop JA; McDonnell PC; Brigham-Burke M; Lyn SD; Minton J; Tan KB; Dede K; Spampanato J; Silverman C; Hensley P; DiPrinzio R; Emery JG; Deen K; Eichman C; Chabot-Fletcher M; Truneh A; Young PR
    J Biol Chem; 1998 Oct; 273(42):27548-56. PubMed ID: 9765287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator.
    Mauri DN; Ebner R; Montgomery RI; Kochel KD; Cheung TC; Yu GL; Ruben S; Murphy M; Eisenberg RJ; Cohen GH; Spear PG; Ware CF
    Immunity; 1998 Jan; 8(1):21-30. PubMed ID: 9462508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuation of graft arterial disease by manipulation of the LIGHT pathway.
    Kosuge H; Suzuki J; Kakuta T; Haraguchi G; Koga N; Futamatsu H; Gotoh R; Inobe M; Isobe M; Uede T
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1409-15. PubMed ID: 15178556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The complementation of lymphotoxin deficiency with LIGHT, a newly discovered TNF family member, for the restoration of secondary lymphoid structure and function.
    Wang J; Foster A; Chin R; Yu P; Sun Y; Wang Y; Pfeffer K; Fu YX
    Eur J Immunol; 2002 Jul; 32(7):1969-79. PubMed ID: 12115617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphotoxin-beta receptor activation by activated T cells induces cytokine release from mouse bone marrow-derived mast cells.
    Stopfer P; Männel DN; Hehlgans T
    J Immunol; 2004 Jun; 172(12):7459-65. PubMed ID: 15187124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential expression of LIGHT and its receptors in human placental villi and amniochorion membranes.
    Gill RM; Ni J; Hunt JS
    Am J Pathol; 2002 Dec; 161(6):2011-7. PubMed ID: 12466117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis.
    Yu KY; Kwon B; Ni J; Zhai Y; Ebner R; Kwon BS
    J Biol Chem; 1999 May; 274(20):13733-6. PubMed ID: 10318773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The lymphotoxin pathway: beyond lymph node development.
    McCarthy DD; Summers-Deluca L; Vu F; Chiu S; Gao Y; Gommerman JL
    Immunol Res; 2006; 35(1-2):41-54. PubMed ID: 17003508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted disruption of LIGHT causes defects in costimulatory T cell activation and reveals cooperation with lymphotoxin beta in mesenteric lymph node genesis.
    Scheu S; Alferink J; Pötzel T; Barchet W; Kalinke U; Pfeffer K
    J Exp Med; 2002 Jun; 195(12):1613-24. PubMed ID: 12070288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of lymphotoxin-beta receptor-mediated cell death by survivin-DeltaEx3.
    You RI; Chen MC; Wang HW; Chou YC; Lin CH; Hsieh SL
    Cancer Res; 2006 Mar; 66(6):3051-61. PubMed ID: 16540654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LIGHT, a member of the TNF superfamily, induces morphological changes and delays proliferation in the human rhabdomyosarcoma cell line RD.
    Hikichi Y; Matsui H; Tsuji I; Nishi K; Yamada T; Shintani Y; Onda H
    Biochem Biophys Res Commun; 2001 Dec; 289(3):670-7. PubMed ID: 11726199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphotoxin-β receptor activation by lymphotoxin-α(1)β(2) and LIGHT promotes tumor growth in an NFκB-dependent manner.
    Daller B; Müsch W; Röhrl J; Tumanov AV; Nedospasov SA; Männel DN; Schneider-Brachert W; Hehlgans T
    Int J Cancer; 2011 Mar; 128(6):1363-70. PubMed ID: 20473944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The three HveA receptor ligands, gD, LT-alpha and LIGHT bind to distinct sites on HveA.
    Sarrias MR; Whitbeck JC; Rooney I; Ware CF; Eisenberg RJ; Cohen GH; Lambris JD
    Mol Immunol; 2000 Aug; 37(11):665-73. PubMed ID: 11164894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-2-induced tumor necrosis factor (TNF)-beta expression: further analysis in the IL-2 knockout model, and comparison with TNF-alpha, lymphotoxin-beta, TNFR1 and TNFR2 modulation.
    Reddy J; Chastagner P; Fiette L; Liu X; Thèze J
    Int Immunol; 2001 Feb; 13(2):135-47. PubMed ID: 11157847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.